ERBB2 and neoplasm: Targeted approaches for adjuvant therapy, such as monoclonal antibody treatment of human epidermal growth factor receptor 2 (HER2)-expressing breast cancer tumors or treatment with checkpoint inhibitors such as anti-PD-L1 (Programmed Death Ligand 1) and PD-1 (Programmed Death Protein 1), have been shown to be effective in slowing down or preventing tumor recurrence but are also associated with treatment-related side effects [3,4,5].